Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol Glucophage Strategy Lifts Stock As Sector Wilts From Medicare Redux

Executive Summary

Bristol-Myers Squibb's diabetes portfolio was a sweetener for the Street as the stock turned in one of the few positive showings among big pharma companies during a quarter marked by increasing political rhetoric over a Medicare drug benefit.

You may also be interested in...



Bergen Pursues Legislative, Managerial Remedies for PharMerica

Reimbursement pressure on Bergen Brunswig's PharMerica long-term care pharmacy business is prompting the parent company to lobby for changes to Medicare's Prospective Payment System.

Bergen Pursues Legislative, Managerial Remedies for PharMerica

Reimbursement pressure on Bergen Brunswig's PharMerica long-term care pharmacy business is prompting the parent company to lobby for changes to Medicare's Prospective Payment System.

Bristol's Orzel Will Be Reviewed By FDA Oncologics Cmte. In September

Bristol-Myers Squibb's colorectal cancer therapy Orzel (UFT/leucovorin) is slated for review in September by FDA's Oncologic Drugs Advisory Committee, Bristol CFO Michael Mee said during a July 21 teleconference discussing the firm's second quarter results.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS034460

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel